P
Prazer Therapeutics
Our Mission is to provide novel therapeutic strategies
About Prazer Therapeutics
Prazer Therapeutics, a South Korean biotechnology firm founded in 2019, is focused on creating therapies for previously untreatable diseases. The company is headquartered in Seoul and its name is a combination of the words "protein" and "eraser," which reflects its mission to treat intractable conditions like neurodegenerative diseases and drug-resistant cancers by removing disease-related proteins. Prazer's core technology is its proprietary SPiDEM™ (Selective Protein Degradation Enabling Moiety) platform, a next-generation approach to Targeted Protein Degradation (TPD). This platform is engineered to overcome the limitations of earlier TPD methods, enabling the degradation of a wider range of targets, including aggregated and membrane proteins that were previously difficult to address. The company is developing orally available and blood-brain barrier-penetrating protein degraders.
The company's business model centers on the research and development of a pipeline of drug candidates, with the goal of entering into joint research and technology transfer agreements with global pharmaceutical companies. Prazer is actively developing new drugs for conditions such as Alzheimer's and Parkinson's diseases, as well as various cancers and inflammatory diseases. Its lead product in development is PRX302, a Tau-targeting agent. The company's work has gained significant recognition, including winning the Seoul BMS Innovation Challenge in 2022 and securing second place in the 2023 Boehringer Ingelheim Innovation Prize in Japan. Prazer has also established strategic collaborations with partners like Yuhan Corporation and Daewon Pharmaceutical.
Prazer Therapeutics has successfully secured substantial funding to advance its research and development efforts. In March 2025, the company closed a ₩29 billion (approximately $20 million) Series B funding round. This round was notably led by Johnson & Johnson Innovation – JJDC, Inc., the venture capital arm of Johnson & Johnson. Other investors included Premier Partners, K2 Investment, Mirae Asset Capital, Quad Asset Management, and STIC Ventures, with follow-on investments from earlier Series A backers like Company K Partners, Kiwoom Investment, and Smilegate Investment. This capital is earmarked for accelerating new drug development and supporting global commercialization. The company is also a member of Johnson & Johnson's JLABS, a global accelerator platform.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Seoul, South Korea
- Employees
- 27
- Open positions
- None listed
- Dealroom signal
- 88.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jul 2026 | $42M | $168M | Premier Partners · Johnson & Johnson Innovation · SmileGate Investment · Underground Ventures | ↗ |
| SERIES BOther financing | Apr 2025 | $24M | $97M | SmileGate Investment · Company K Partners · Kiwoom Investment · K2 Investment Partners | ↗ |
Growth signals
Latest recorded traffic for Prazer Therapeutics is 2.3K monthly website visits, down 69.7% over the last three months. Prazer Therapeutics's team grew 42.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Prazer Therapeutics in the Seoul ecosystem
The Prazer Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Johnson & Johnson Innovation
SmileGate Investment
Company K Partners- KIKiwoom Investment
K2 Investment Partners
STIC Ventures- QMQuad Asset Management
Premier Partners
Mirae Asset Capital
Series B and later8 investors entered at this stage
Underground Ventures
K2 Investment
Hana Securities- C(Chant Venture Fund (I.L.P)
Shinhan Asset Management- GLGO INVEST LLC
Mirae Asset Securities
Woori Venture Partners
Other known investors1 additional known investor
Kyung Hee University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Prazer Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Prazer Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










